Major drug manufacturers have actively engaged with local partners, establishing production and distribution channels tailored to the countrys needs
Patients should inspect their semaglutide before each injection
Supplements should only be used to correct confirmed deficiencies, and high-dose formulations should be avoided unless specifically prescribed
As it is not approved by the FDA, compounded semaglutide is a cash-pay product that bypasses the complex insurance billing
Divi's Laboratories is already supplying semaglutide components globally Price compression will occur Not immediately, and not to generic-drug levels, but a ~50% reduction from current branded pricing is a reasonable baseline expectation based on biosimilar precedent in other biologic classes New formulations will compete Novo Nordisk's oral semaglutide (approved December 2025 by the FDA and launched in early 2026) and the newly FDA-approved once-daily oral GLP-1 orforglipron (Foundayo, approved April 1, 2026) represent the manufacturer's strategy for maintaining market share through innovation beyond the injectable The arrival of biosimilar competition does not mean branded products disappear
Source: FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014
